Abstract: The present invention is related to the production of bio-based carotenoids, particularly to methods for enhancing the titer and purity of beta-carotene fermentation in a suitable host cell.

Abstract: The present invention relates to a composition for preventing or treating obesity or sarcopenia, containing ATPase inhibitory factor 1 (IF1) and, more specifically, to a pharmaceutical composition and a food for preventing or treating obesity or sarcopenia, containing, as an active ingredient, IF1 having an effect of suppressed appetite or effects increased muscle mass and muscle production. According to the present invention, ATPase inhibitory factor 1 (IF1) exhibits, in an obesity-induced mouse model, effects of inhibited weight gain and decreased dietary intake without side effects, and exhibits, in obesity-induced or aged mouse, effects of increased muscle mass, increased muscle protein and muscle production, and thus is very useful as an agent for preventing, alleviating or treating metabolic diseases such as obesity, an agent for suppressing appetite and an agent for preventing, alleviating or treating muscle loss-related diseases such as sarcopenia.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided.

Abstract: A disposable test cartridge to determine the concentration of one or more liver enzymes in a blood sample includes a cartridge body having a plurality of chambers where at least one of the chambers contains a reactant mixture that reacts when catalyzed by one of the liver enzymes ALT, AST, ALP, or GGT in a blood sample forming a reaction solution, a removable cartridge cover connected to the cartridge body, and a test strip module connected to the cartridge body. The test strip module containing at least one analyte test strip configured for receiving a portion of the reaction solution and electrochemically measuring at least one analyte that is a reaction product in the reaction solution.

Abstract: Provided is a use of Megamonas funiformis in the prevention and/or treatment of metabolic diseases. Megamonas funiformis has the function of preventing and/or treating metabolic diseases (such as obesity, diabetes, atherosclerosis-related diseases, cardiovascular disease and hyperuricemia).

Abstract: The present teachings relate to methods, systems, and kits for the preparation, purification and/or analysis of a glycan or glycoconjugate, and specifically to a magnetic bead based sample preparation protocol. In some aspects, the sample preparation protocol can provide for glycoconjugate capture, glycan release, fluorescent derivatization, and glycan purification for subsequent capillary electrophoresis, liquid chromatography, or other glycoanalytical method using magnetic beads containing negatively charged carboxyl groups extending from the surface of the magnetic beads.

Abstract: Antibodies that bind Her2, EGFR, Trop2, CDH3 or other TAAs containing a triple mutation at L234A, L235A, and L328C and methods of making such triple mutated antibodies are disclosed herein. Consequently, the triple mutated antibodies contain a modified effector function through Fc silencing and are capable of site-specific conjugation at L328C to form an antibody-drug-conjugate (ADC) which can be administered to patients and provide a method of treating cancer, immunological and neurological disorders.

Abstract: The present application relates to a GD2-based chimeric antigen receptor comprising an antigen-binding domain, a transmembrane domain, a costimulatory signaling domain, a CD3? signaling domain, and a self-destructive domain in tandem arrangement; wherein the antigen-binding domain binds to a tumor surface antigen, wherein the tumor surface antigen is GD2, and the antigen-binding domain is a single-chain antibody against the tumor surface antigen GD2, wherein the self-destructive domain is a caspase 9 domain.

Abstract: The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.

Abstract: Provided herein are methods and compositions relating to variant nucleic acid libraries encoding for antibodies including single domain antibodies. Libraries generated using methods described herein have improved characteristics including improved binding affinity. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Abstract: The present invention relates to methods of activating live lactic acid bacteria comprising exposing said bacteria to a preparation comprising citrate, wherein said bacteria have the ability to utilize citrate as an external electron acceptor. The present invention further relates to methods to enhance the activity of certain live bacteria in mammals. More specifically the invention relates to improve the wake-up of certain lactic acid bacteria from the freeze-dried state. The present invention also relates to preparations comprising said activated bacteria and therapeutic uses of said activated bacteria.

Abstract: Some configurations of a microfluidic apparatus can comprise a fluidic circuit of interconnected fluidic structures into which a plurality of different media can be introduced or extracted. A variety of operations can be performed with the different media including isolating with a second medium one or more of the fluidic structures that is filled partially or fully with a first medium. Discrete volumes of a medium can be moved through the isolating second medium to deliver materials or micro-objects to or remove micro-objects or materials from a fluidic structure that is otherwise isolated by the second medium. Some configurations of a microfluidic apparatus can isolate microfluidic structures in a microfluidic apparatus using flow rates or blocking structures, and some configurations can manage bubbles in fluidic structures.

Abstract: The present disclosure provides methods of alleviating a symptom or delaying disease progression of a condition associated with a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor and/or treating a condition associated with a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor. The present methods result in alleviating a symptom or delaying disease progression of the condition associated with the thiamine deficiency, the thiamine-dependent enzyme, or the associated cofactor, treatment of the condition associated with the thiamine deficiency, the thiamine-dependent enzyme, or the associated cofactor, and/or alteration of a phenotypic characteristic of the condition associated with the thiamine deficiency, the thiamine-dependent enzyme, or the associated cofactor.

Abstract: The present invention refers to polypeptides with asparaginase activity that have an increased rate of self-processing compared to human wild L-asparaginase (ASRGLI), resulting from a mutation in the ASRGLI glycine rich loop called HGG loop (Histidine 8-Glycine 9-Glycine 10). Polynucleotides that encode the polypeptides of invention are also described herein. Expression cassettes comprising said polynucleotides, expression vectors, host cells, pharmaceutical compositions, uses of the invention polypeptide in the manufacture of a preventive medicine or cancer treatment and methods to produce the polypeptide of invention and to prevent or treat cancer are also described.

Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.

Abstract: The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source.

Abstract: A method of isolating a pluripotent cell from human umbilical cord is described herein. Cells so isolated may be reprogrammed as pluripotent cells and differentiated for use in cardiovascular treatment, may be used in screening cardiovascular drug candidates, or may be used in cell-based and cell-free therapy for inflammatory conditions. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 13 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Cells obtained in this way can be differentiated for use in treating conditions of cell damage, by supplanting the function of a damaged cell in a condition such as spinal cord injury, cardiovascular injury or heart disease.

Abstract: Disclosed herein are monoclonal antibodies that specifically bind to human mature Factor D and that do not bind to human Pro-Factor D, monoclonal antibodies that specifically bind to human Pro-Factor D and do not bind to human mature Factor D, and monoclonal antibodies that bind to both human mature Factor D and human Pro-Factor D. Also disclosed are methods of using the monoclonal antibodies, and compositions comprising the same, for detection of the mature and/or the pro-form of Factor D in biological samples, to determine the status of the Alternative Pathway of Complement (APC) in a mammalian subject, or to determine the status of Factor D after treatment with a MASP-3 inhibitory agent which inhibits the conversion of Pro-Factor D to mature Factor D.

Abstract: Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiotaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.